89 citations
,
February 1993 in “Journal of Medicinal Chemistry” New compounds called benzoquinolinones may treat conditions linked to excess DHT.
46 citations
,
March 2001 in “Journal of endocrinological investigation” 5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.
37 citations
,
January 2009 in “Sexual Development” Fadrozole and Finasteride change frog sex ratios and cause intersex animals with altered gene expressions.
27 citations
,
October 2001 in “Journal of Medicinal Chemistry” Researchers found new potential but less potent rat enzyme inhibitors using a 3D model.
20 citations
,
February 2002 in “Expert Opinion on Therapeutic Patents” New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
3 citations
,
October 1995 in “International Journal of Dermatology” Finasteride helps treat skin issues like acne and baldness by blocking testosterone conversion.
1 citations
,
January 2015 in “Hair therapy & transplantation” New drug dutasteride effectively treats hair loss, but use cautiously due to potential sexual side effects.
These medications for BPH have known risks and may have new side effects.
These medications for BPH have known risks and may have new side effects.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
January 2022 in “Asian journal of Current Research in Clinical Cancer” Some dibenzo compounds might help treat cancer with fewer side effects.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
44 citations
,
December 2005 in “The Journal of Steroid Biochemistry and Molecular Biology” Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.
November 2025 in “Russian Journal of Oncology” Modifying steroidal inhibitors shows promise for developing new cancer treatments.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
235 citations
,
September 2004 in “The Journal of urology/The journal of urology” Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
223 citations
,
December 2010 in “The Journal of Sexual Medicine” Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
147 citations
,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
147 citations
,
April 1990 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride safely lowers DHT levels without affecting testosterone.
137 citations
,
March 2006 in “Cns Drug Reviews” Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.
124 citations
,
March 2012 in “JAMA” Testosterone's muscle-building effects do not require its conversion to DHT.
124 citations
,
January 1993 in “The Prostate” Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.
111 citations
,
August 2015 in “Reviews in Endocrine and Metabolic Disorders” 5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.
90 citations
,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
75 citations
,
November 1996 in “Fertility and Sterility” Finasteride effectively reduces hair growth in women with idiopathic hirsutism, but requires careful contraception during treatment.
66 citations
,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
66 citations
,
June 2013 in “Journal of Dermatological Treatment” Finasteride and dutasteride effectively treat hair loss, but may cause side effects like sexual dysfunction and depression.